The Top Line Novo Nordisk’s chief scientific officer looks to the future of GLP-1s
Dec 13, 2024
Marcus Schindler, Novo Nordisk’s chief scientific officer and executive VP of research, discusses the breakthrough success of GLP-1 agonists like semaglutide in treating Type 2 diabetes and obesity. He reveals exciting innovations in dosing strategies and emerging applications in neurodegenerative diseases. Schindler also highlights the integration of psi RNA technology for better chronic disease management and the transformative impact of AI on drug development. His insights showcase how Novo Nordisk is innovating and collaborating to tackle significant health challenges.
AI Snips
Chapters
Transcript
Episode notes
GLP-1 Agonists: Future Directions
- Semaglutide's success highlights the potential of GLP-1 agonists in treating chronic diseases.
- Further research aims to improve efficacy, maintain weight loss, and explore new drug delivery methods like a "vaccine-type" GLP-1.
Infrequent Dosing: A Holy Grail
- Once-monthly dosing is a goal for obesity treatments to improve patient compliance and convenience.
- Novo Nordisk is exploring different approaches, including collaborations and new drug delivery technologies, to achieve this.
Oral Semaglutide's Scalability Challenge
- Oral semaglutide for diabetes exists, but its lower efficacy requires higher doses, impacting manufacturing.
- Novo Nordisk is actively working on improving oral semaglutide's efficacy to address scalability challenges.